News Hansa closes on FDA verdict for transplant drug imlifidase The FDA has started reviewing Hansa's imlifidase for highly sensitised adults needing a kidney transplant, but not in the requested rapid timeframe.
News Quell takes new Treg into clinic after transplant study halt Quell Therapeutics changes tack, starting trials of a CAR-Treg in rheumatoid arthritis and systemic sclerosis and parking its transplant therapy.
R&D Xenotransplantation at the brink of breakthrough: A new era ... In a landmark procedure performed at Massachusetts General Hospital (MGH) on 25th January 2025, a 66-year-old man with end-stage renal disease (ESRD) received a genetically modif
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.